Korczyn AD - Search Results

1

A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.

Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F; 043 Study Group. Brunt ER, et al. Among authors: korczyn ad. J Neural Transm (Vienna). 2002 Apr;109(4):489-502. doi: 10.1007/s007020200040. J Neural Transm (Vienna). 2002. PMID: 11956968 Clinical Trial.

2

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.

Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F. Korczyn AD, et al. Mov Disord. 1998 Jan;13(1):46-51. doi: 10.1002/mds.870130112. Mov Disord. 1998. PMID: 9452325 Clinical Trial.

3

A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.

Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. Korczyn AD, et al. Neurology. 1999 Jul 22;53(2):364-70. doi: 10.1212/wnl.53.2.364. Neurology. 1999. PMID: 10430427 Clinical Trial.

4

Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.

Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, Abdalla M; 056 Study Group. Rascol O, et al. Among authors: korczyn ad. Mov Disord. 2006 Nov;21(11):1844-50. doi: 10.1002/mds.20988. Mov Disord. 2006. PMID: 16958094 Clinical Trial.

5

Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.

Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Rascol O, et al. Among authors: korczyn ad. Mov Disord. 1998 Jan;13(1):39-45. doi: 10.1002/mds.870130111. Mov Disord. 1998. PMID: 9452324 Clinical Trial.

6

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. Rascol O, et al. Among authors: korczyn ad. N Engl J Med. 2000 May 18;342(20):1484-91. doi: 10.1056/NEJM200005183422004. N Engl J Med. 2000. PMID: 10816186 Free article. Clinical Trial.

7

Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials.

Rabey JM, Bass H, Bonuccelli U, Brooks D, Klotz P, Korczyn AD, Kraus P, Martinez-Martin P, Morrish P, Van Sauten W, Van Hilten B. Rabey JM, et al. Among authors: korczyn ad. Clin Neuropharmacol. 1997 Aug;20(4):322-37. Clin Neuropharmacol. 1997. PMID: 9260730 Clinical Trial.

8

Freezing of gait in patients with advanced Parkinson's disease.

Giladi N, Treves TA, Simon ES, Shabtai H, Orlov Y, Kandinov B, Paleacu D, Korczyn AD. Giladi N, et al. Among authors: korczyn ad. J Neural Transm (Vienna). 2001;108(1):53-61. doi: 10.1007/s007020170096. J Neural Transm (Vienna). 2001. PMID: 11261746

9

Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease.

Giladi N, Treves TA, Paleacu D, Shabtai H, Orlov Y, Kandinov B, Simon ES, Korczyn AD. Giladi N, et al. Among authors: korczyn ad. J Neural Transm (Vienna). 2000;107(1):59-71. doi: 10.1007/s007020050005. J Neural Transm (Vienna). 2000. PMID: 10809404

10

Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease.

Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Merims D, et al. Among authors: korczyn ad. J Neural Transm (Vienna). 2004 Oct;111(10-11):1447-53. doi: 10.1007/s00702-004-0209-9. J Neural Transm (Vienna). 2004. PMID: 15480845

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

713 results

Search Page

Filters